Hookipa Pharma Inc. HOOK, -2.34% shares jumped 40% in late trading Thursday after the company announced that the Food and Drug Administration approved a study of the company’s immunotherapy approach to certain cancers. Hookipa had asked the FDA for clearance on a phase 1/2 study of HB-201, and with its approval will now start its first clinical trial in immuno-oncology, the company said. “With the FDA’s clearance of our IND application we have achieved an important milestone advancing HB-201 into clinical development,” Chief Executive Joern Aldag said in the announcement. Hookipa, which went public in April, closed Thursday at $6.68, but shares neared $9.50 in after-hours trading following the announcement.